The global clinical nutrition market generated $39,339.4 million in 2015 and is projected to advance at a CAGR of 5.4% during the forecast period (2016–2022). Factors such as the rising aging population, birth rate, and premature births have been observed as the key drivers for the market. Globally, malnutrition, which refers to the deficiency of critical nutrients in the body, is a common problem. In 2010, over 40% of patients globally were recorded as being malnourished. In 2012, over 33% of the patients in Europe were found to be malnourished. Further, according to an article published in 2012, the cost incurred for treating malnutrition by the European government surged to $237.0 billion per year, and this expenditure could be reduced by leveraging the advantages of clinical nutrition products, as they are an effective and affordable method of treating malnutrition.
In 2015, based on product, the infant nutrition category garnered the major share in the clinical nutrition market. Infant formulae are readily available at supermarkets and via other distribution channels. Infant nutrition is available in three forms: liquid concentrate, powder, and ready-to-feed. Liquid concentrates and powders are more affordable. On the contrary, ready-to-feed formulae are convenient, as they can be consumed directly. Some major market players offering infant nutrition products are Abbott Laboratories, Mead Johnson & Company LLC, Danone S.A. and Nestle S.A.
The increase in the number of cancer cases and central nervous system (CNS) diseases is a major growth driver for the enteral nutrition category of the clinical nutrition market. Enteral nutrition supplements are used to during the treatment of CNS disorders and cancer, as these ensure that all essential nutrients reach patients. Cancer leads to low appetite, which results in malnutrition, and thus continuous nutrient intake is required. According to the World Health Organization, in 2012, globally around 14.1 million new cancer cases, around 8.2 million deaths due to cancer, and over 32.6 million people, in total, had cancer. Further, underdeveloped countries accounted for around 57% (8 million) of new cancer cases and 65% (5.3 million) of the cancer deaths across the world.
In 2015, Asia-Pacific (APAC) dominated the clinical nutrition market by capturing an over 40.0% share. Further, APAC is projected to witness the fastest growth during 2016–2022. The rising birth rate and aging population are the major growth drivers for the APAC market. In 2010, the population of people over the age of 65 in APAC was estimated to be 288.0 million, and this number is projected to surpass 911.0 million by 2050. Further, the rising number of cases of malnutrition in the region is projected to lead to an increase in the demand for clinical nutrition products.
Additionally, with a rise in the disposable income, increase in healthcare expenses, and surge in the awareness pertaining to nutrition, substantial growth in the APAC clinical nutrition market is predicted for the forecast period. Further, regional governments are campaigning to raise the awareness about the dangers of improper nutrition in their countries, which is leading to the increased consumption of nutritional diet. This is expected to augment the growth of the APAC market in the coming years.
Some of the major players operating in the global clinical nutrition market are Abbott Laboratories, B. Braun Melsungen AG, Baxter International Inc., Nestlé S.A., Perrigo Company PLC, Danone S.A., Mead Johnson & Company LLC, and Fresenius Kabi AG.
Clinical Nutrition Market Segmentation